Kyverna Therapeutics, Inc. (KYTX) stock
KYTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$4.48−0.22 (-4.68%)
Close on Nov 18, 2026Market cap $277.06MP/E –Yield –
Kyverna Therapeutics price to book ratio
The price-to-book ratio is market cap divided by shareholders' equity.
Kyverna Therapeutics's price to book ratio was 1.9× on Nov 11, 2026, against 2.2× a year earlier. Over the last 3 years it ranged from 0.3× to 3.2×, with a median of 1.4×.
Price to Book Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 1.9× | −0.8 |
| 2025 | Dec 31, 2025 | 2.7× | +2.2 |
| 2024 | Dec 31, 2024 | 0.5× | – |
See a number that looks wrong?